Table 3

Reasons for and evaluation of switching to glargine 300 (Gla-300)

Patients*Physicians†
Reasons for switching to Gla-300
  Quality of life67 (48.60%)35 (21.60%)
   (Fear of) hypoglycemia14 (10.10%)26 (16%)
  Treatment satisfaction15 (10.90%)7 (4.30%)
  Dose (less volume)96 (69.60%)102 (63%)
  Flexibility46 (33.30%)40 (24.70%)
  Adherence3 (2.20%)0 (0%)
  Hemoglobin A1c19 (13.80%)36 (22.20%)
Evaluation of switching to Gla-300
   Worse than expected4 (2.80%)3 (2.10%)
   Slightly worse than expected7 (4.90%)13 (9%)
  As expected48 (33.60%)58 (40%)
  Slightly better than expected28 (19.60%)24 (16.50%)
  Better than expected56 (39.10%)47 (32.40%)
  • *The n regarding reasons for switching to Gla-300 is 138; the n regarding evaluation of Gla-300 is 143.

  • †The n regarding reasons for switching to Gla-300 is 162; the n regarding evaluation of Gla-300 is 145.